Yes, I see where you are coming from with that. The clinical trials should be the really expensive part and the analysis should be at a lower cost.
There will be other expenses - and general non research expenses look like they are over $200k per quarter.
BIT will still need to create more cash moving forward so, it is prudent to have a CR soon. All companies do that and BIT will have to set itself up for the immediate future. CR is not a dirty word - just a management tool
Thanks for pointing that out.
$30 Billion Deal, page-4688
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.0¢ |
Change
0.005(11.1%) |
Mkt cap ! $45.11M | |||
| Open | High | Low | Value | Volume |
| 4.6¢ | 5.2¢ | 4.6¢ | $42.25K | 871.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.2¢ | 155000 | 2 |
View Market Depth
| Last trade - 15.51pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
5.0¢ |
Change
0.005 ( 8.70 %) |
||||
| Open | High | Low | Volume | ||
| 4.6¢ | 5.1¢ | 4.6¢ | 221683 | ||
| Last updated 15.49pm 14/06/2024 ? | |||||
| BIT (ASX) Chart |